{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:11:41Z","timestamp":1778829101467,"version":"3.51.4"},"reference-count":184,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Government of India Department of Biotechnology","doi-asserted-by":"publisher","award":["BT\/PR26897\/NNT\/28\/1489\/2017"],"award-info":[{"award-number":["BT\/PR26897\/NNT\/28\/1489\/2017"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["3\/1\/3\/JRF-2019\/HRD"],"award-info":[{"award-number":["3\/1\/3\/JRF-2019\/HRD"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ajps.2022.02.001","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T09:25:47Z","timestamp":1644744347000},"page":"153-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Delivery strategies for CRISPR\/Cas genome editing tool for retinal dystrophies: challenges and opportunities"],"prefix":"10.1016","volume":"17","author":[{"given":"Aayushi","family":"Lohia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak Kumar","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd","family":"Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indumathi","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupama","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4174-7664","authenticated-orcid":false,"given":"Deepak","family":"Chitkara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajps.2022.02.001_bib0001","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrmicro3096","article-title":"Revenge of the phages: defeating bacterial defences","volume":"11","author":"Samson","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0002","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1124\/jpet.119.257287","article-title":"CRISPR\/Cas system for genome editing: progress and prospects as a therapeutic tool","volume":"370","author":"Sahel","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0003","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1099\/mic.0.023960-0","article-title":"Short motif sequences determine the targets of the prokaryotic CRISPR defence system","volume":"155","author":"Mojica","year":"2009","journal-title":"Microbiology (Reading, Engl.)"},{"key":"10.1016\/j.ajps.2022.02.001_bib0004","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcancer.2018.04.001","article-title":"CRISPR\/Cas9 for cancer research and therapy","volume":"55","author":"Zhan","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0005","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrmicro2577","article-title":"Evolution and classification of the CRISPR-Cas systems","volume":"9","author":"Makarova","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0006","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5604\/01.3001.0009.2114","article-title":"CRISPR-Cas systems in prokaryotes","volume":"64","author":"Burmistrz","year":"2015","journal-title":"Pol J Microbiol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0007","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13059-018-1534-x","article-title":"CRISPR-Cas9 off-targeting assessment with nucleic acid duplex energy parameters","volume":"19","author":"Alkan","year":"2018","journal-title":"Genome Biol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0008","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1111\/febs.13110","article-title":"Genome modification by CRISPR\/Cas9","volume":"281","author":"Ma","year":"2014","journal-title":"FEBS J"},{"key":"10.1016\/j.ajps.2022.02.001_bib0009","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00284-018-1547-4","article-title":"CRISPR-Cas system: history and prospects as a genome editing tool in microorganisms","volume":"75","author":"Javed","year":"2018","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13059-016-1012-2","article-title":"Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR","volume":"17","author":"Haeussler","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0011","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/genes10090654","article-title":"Molecular therapies for inherited retinal diseases-current standing, opportunities and challenges","volume":"10","author":"V\u00e1zquez-Dom\u00ednguez","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ajps.2022.02.001_bib0012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.preteyeres.2018.03.003","article-title":"CRISPR-Cas9 genome engineering: treating inherited retinal degeneration","volume":"65","author":"Burnight","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0014","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv"},{"key":"10.1016\/j.ajps.2022.02.001_bib0015","doi-asserted-by":"crossref","first-page":"14500","DOI":"10.1038\/ncomms14500","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajps.2022.02.001_bib0016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR\u2013Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ajps.2022.02.001_bib0017","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ajps.2022.02.001_bib0018","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ajps.2022.02.001_bib0019","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly efficient Cas9-mediated transcriptional programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.ajps.2022.02.001_bib0020","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022 T to G\u2022 C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ajps.2022.02.001_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms16026","article-title":"Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein","volume":"8","author":"Lei","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajps.2022.02.001_bib0022","doi-asserted-by":"crossref","first-page":"11870","DOI":"10.1073\/pnas.1515692112","article-title":"CASFISH: cRISPR\/Cas9-mediated in situ labeling of genomic loci in fixed cells","volume":"112","author":"Deng","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2021.113207","article-title":"Rapid and accurate nucleobase detection using FnCas9 and its application in COVID-19 diagnosis","volume":"183","author":"Azhar","year":"2021","journal-title":"Biosens. Bioelectron"},{"key":"10.1016\/j.ajps.2022.02.001_bib0024","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/014107680609900417","article-title":"Genetics of inherited retinal disease","volume":"99","author":"Francis","year":"2006","journal-title":"J R Soc Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.neuro.26.041002.131416","article-title":"Progress toward understanding the genetic and biochemical mechanisms of inherited photoreceptor degenerations","volume":"26","author":"Pacione","year":"2003","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0026","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-3-030-27378-1_43","article-title":"Emerging drug therapies for inherited retinal dystrophies","volume":"1185","author":"Sundaramurthi","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0027","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","article-title":"The molecular basis of human retinal and vitreoretinal diseases","volume":"29","author":"Berger","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0028","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2017.10.004","article-title":"Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives","volume":"63","author":"Dias","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0029","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1172\/JCI120429","article-title":"Gene therapy and genome surgery in the retina","volume":"128","author":"DiCarlo","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.ajps.2022.02.001_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/genes8020053","article-title":"Correction of monogenic and common retinal disorders with gene therapy","volume":"8","author":"Sengillo","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ajps.2022.02.001_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2016.09.001","article-title":"In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies","volume":"56","author":"Yanik","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0032","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1089\/hum.2012.123","article-title":"Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients","volume":"23","author":"Colella","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0033","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1089\/hum.2012.123","article-title":"Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients","volume":"23","author":"Colella","year":"2012","journal-title":"Human gene therapy"},{"key":"10.1016\/j.ajps.2022.02.001_bib0034","first-page":"125","article-title":"Intraocular delivery of recombinant virus","volume":"47","author":"Liang","year":"2001","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/humc.2015.29001.sch","article-title":"Investor outlook: focus on upcoming LCA2 gene therapy phase III results","volume":"26","author":"Schimmer","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.ajps.2022.02.001_bib0036","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ajps.2022.02.001_bib0037","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nbt.3659","article-title":"Applications of CRISPR technologies in research and beyond","volume":"34","author":"Barrangou","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0038","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.omtn.2018.11.016","article-title":"Programmable molecular scissors: applications of a new tool for genome editing in biotech","volume":"14","author":"Saha","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.ajps.2022.02.001_bib0039","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.preteyeres.2008.05.003","article-title":"Leber congenital amaurosis: genes, proteins and disease mechanisms","volume":"27","author":"den Hollander","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0040","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1167\/iovs.03-1230","article-title":"Impairment of the transient pupillary light reflex in Rpe65(-\/-) mice and humans with leber congenital amaurosis","volume":"45","author":"Aleman","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0041","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1167\/iovs.07-0068","article-title":"Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients","volume":"48","author":"Simonelli","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0042","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/hmg\/ddx438","article-title":"Cas9\/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery","volume":"27","author":"Giannelli","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ajps.2022.02.001_bib0043","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ophtha.2018.04.001","article-title":"Clustered regularly interspaced short palindromic repeats-based genome surgery for the treatment of autosomal dominant retinitis pigmentosa","volume":"125","author":"Tsai","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajps.2022.02.001_bib0044","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0045","first-page":"523","article-title":"Genome surgery and gene therapy in retinal disorders","volume":"90","author":"Chan","year":"2017","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0046","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajps.2022.02.001_bib0047","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ymthe.2018.10.009","article-title":"Long-term effects of in vivo genome editing in the mouse retina using campylobacter jejuni Cas9 expressed via adeno-associated virus","volume":"27","author":"Jo","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0048","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1101\/gr.219089.116","article-title":"Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration","volume":"27","author":"Kim","year":"2017","journal-title":"Genome Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0049","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/APO.0000000000000227","article-title":"Retinitis pigmentosa: progress and perspective","volume":"5","author":"Zhang","year":"2016","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.ajps.2022.02.001_bib0050","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis pigmentosa","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet (Lond)"},{"key":"10.1016\/j.ajps.2022.02.001_bib0051","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20041447","article-title":"Loss of synchronized retinal phagocytosis and age-related blindness in mice lacking alphavbeta5 integrin","volume":"200","author":"Nandrot","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0052","doi-asserted-by":"crossref","first-page":"12005","DOI":"10.1073\/pnas.0704756104","article-title":"Essential role for MFG-E8 as ligand for alphavbeta5 integrin in diurnal retinal phagocytosis","volume":"104","author":"Nandrot","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajps.2022.02.001_bib0053","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1101\/gr.144105.112","article-title":"Autozygome-guided exome sequencing in retinal dystrophy patients reveals pathogenetic mutations and novel candidate disease genes","volume":"23","author":"Abu-Safieh","year":"2013","journal-title":"Genome Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0054","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/gim.2015.127","article-title":"Expanding the clinical, allelic, and locus heterogeneity of retinal dystrophies","volume":"18","author":"Patel","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0055","first-page":"369","article-title":"Novel mutations in MERTK associated with childhood onset rod-cone dystrophy","volume":"16","author":"Mackay","year":"2010","journal-title":"Mol Vis"},{"key":"10.1016\/j.ajps.2022.02.001_bib0056","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5301\/ejo.5000096","article-title":"Homozygous mutation in MERTK causes severe autosomal recessive retinitis pigmentosa","volume":"22","author":"Ksantini","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0057","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1167\/iovs.12-11541","article-title":"Mutations in the X-linked retinitis pigmentosa genes RPGR and RP2 found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa","volume":"54","author":"Churchill","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0058","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ng0596-35","article-title":"A gene (RPGR) with homology to the RCC1 guanine nucleotide exchange factor is mutated in X-linked retinitis pigmentosa (RP3)","volume":"13","author":"Meindl","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajps.2022.02.001_bib0059","first-page":"3373","article-title":"Complex expression pattern of RPGR reveals a role for purine-rich exonic splicing enhancers","volume":"43","author":"Hong","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0060","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1073\/pnas.96.4.1315","article-title":"The retinitis pigmentosa GTPase regulator, RPGR, interacts with the delta subunit of rod cyclic GMP phosphodiesterase","volume":"96","author":"Linari","year":"1999","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.ajps.2022.02.001_bib0061","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/mt.2015.220","article-title":"In vivo CRISPR\/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa","volume":"24","author":"Bakondi","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0062","doi-asserted-by":"crossref","first-page":"19969","DOI":"10.1038\/srep19969","article-title":"Precision medicine: genetic repair of retinitis pigmentosa in patient-derived stem cells","volume":"6","author":"Bassuk","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajps.2022.02.001_bib0063","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1038\/mtna.2016.92","article-title":"In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR\/Cas9 in the mouse retina","volume":"5","author":"Latella","year":"2016","journal-title":"Mol Ther Nucl Acids"},{"key":"10.1016\/j.ajps.2022.02.001_bib0064","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet (Lond)"},{"key":"10.1016\/j.ajps.2022.02.001_bib0065","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2147\/OPTH.S65732","article-title":"Recent advances and future prospects in choroideremia","volume":"9","author":"Zinkernagel","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0066","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1167\/iovs.06-0424","article-title":"Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations","volume":"47","author":"Jacobson","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0067","doi-asserted-by":"crossref","first-page":"8415","DOI":"10.1073\/pnas.1506960112","article-title":"Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization","volume":"112","author":"Charbel Issa","year":"2015","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.ajps.2022.02.001_bib0068","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11427-013-4443-y","article-title":"Dawn of ocular gene therapy: implications for molecular diagnosis in retinal disease","volume":"56","author":"Zaneveld","year":"2013","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0069","doi-asserted-by":"crossref","first-page":"R262","DOI":"10.1093\/hmg\/ddl205","article-title":"Usher syndrome: molecular links of pathogenesis, proteins and pathways","author":"Kremer","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ajps.2022.02.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5056279","article-title":"Guiding lights in genome editing for inherited retinal disorders: implications for gene and cell therapy","volume":"2018","author":"Sanjurjo-Soriano","year":"2018","journal-title":"Neural Plast"},{"key":"10.1016\/j.ajps.2022.02.001_bib0071","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.omtn.2017.08.003","article-title":"USH2A Gene editing using the CRISPR system","volume":"8","author":"Fuster-Garc\u00eda","year":"2017","journal-title":"Mol Ther Nucl Acids"},{"key":"10.1016\/j.ajps.2022.02.001_bib0072","first-page":"61","article-title":"Evolution of choroidal neovascular membrane in best disease after single intravitreal bevacizumab. Case report","volume":"10","author":"Celea","year":"2015","journal-title":"Maedica"},{"key":"10.1016\/j.ajps.2022.02.001_bib0073","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ajhg.2020.06.011","article-title":"Human iPSC modeling reveals mutation-specific responses to gene therapy in a genotypically diverse dominant maculopathy","volume":"107","author":"Sinha","year":"2020","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ajps.2022.02.001_bib0074","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.stemcr.2019.09.010","article-title":"Morphological and molecular defects in human three-dimensional retinal organoid model of X-linked juvenile retinoschisis","volume":"13","author":"Huang","year":"2019","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.ajps.2022.02.001_bib0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s004390100461","article-title":"A summary of 20 CACNA1F mutations identified in 36 families with incomplete X-linked congenital stationary night blindness, and characterization of splice variants","volume":"108","author":"Boycott","year":"2001","journal-title":"Hum Genet"},{"key":"10.1016\/j.ajps.2022.02.001_bib0076","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ajhg.2009.10.012","article-title":"Mutations in TRPM1 are a common cause of complete congenital stationary night blindness","volume":"85","author":"van Genderen","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ajps.2022.02.001_bib0077","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber's congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0078","doi-asserted-by":"crossref","first-page":"eaax1210","DOI":"10.1126\/sciadv.aax1210","article-title":"CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis","volume":"5","author":"Jo","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.ajps.2022.02.001_bib0079","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ymthe.2017.05.015","article-title":"Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration","volume":"25","author":"Burnight","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omtn.2017.08.016","article-title":"In vivo knockout of the vegfa gene by Lentiviral delivery of CRISPR\/Cas9 in mouse retinal pigment epithelium cells","volume":"9","author":"Holmgaard","year":"2017","journal-title":"Mol Ther Nucl acids"},{"key":"10.1016\/j.ajps.2022.02.001_bib0081","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04175-y","article-title":"CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration","volume":"9","author":"Koo","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ajps.2022.02.001_bib0082","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.3390\/cells9102214","article-title":"Progressive photoreceptor dysfunction and age-related macular degeneration-like features in rp1l1 mutant zebrafish","volume":"9","author":"Noel","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ajps.2022.02.001_bib0083","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/iovs.61.4.31","article-title":"In vivo CRISPR\/Cas9-mediated genome editing mitigates photoreceptor degeneration in a mouse model of X-linked retinitis pigmentosa","volume":"61","author":"Hu","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0084","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/crispr.2017.0009","article-title":"Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for rhodopsin-associated dominant retinitis pigmentosa","volume":"1","author":"Li","year":"2018","journal-title":"CRISPR J"},{"key":"10.1016\/j.ajps.2022.02.001_bib0085","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/mt.2016.107","article-title":"CRISPR repair reveals causative mutation in a preclinical model of retinitis pigmentosa","volume":"24","author":"Wu","year":"2016","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ajps.2022.02.001_bib0086","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1038\/s41598-017-07153-4","article-title":"Modeling dominant and recessive forms of retinitis pigmentosa by editing three rhodopsin-encoding genes in xenopus laevis using CRISPR\/Cas9","volume":"7","author":"Feehan","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajps.2022.02.001_bib0087","doi-asserted-by":"crossref","first-page":"14716","DOI":"10.1038\/ncomms14716","article-title":"Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice","volume":"8","author":"Yu","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajps.2022.02.001_bib0088","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.omtn.2017.08.003","article-title":"USH2A gene editing using the CRISPR system","volume":"8","author":"Fuster-Garcia","year":"2017","journal-title":"Mol Ther Nucl acids"},{"key":"10.1016\/j.ajps.2022.02.001_bib0089","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.omtm.2019.11.016","article-title":"Genome editing in patient iPSCs corrects the most prevalent USH2A mutations and reveals intriguing mutant mRNA expression profiles","volume":"17","author":"Sanjurjo-Soriano","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ajps.2022.02.001_bib0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fnmol.2017.00453","article-title":"Recapitulating X-linked juvenile retinoschisis in mouse model by knock-in patient-specific novel mutation","volume":"10","author":"Chen","year":"2018","journal-title":"Fron Mol Neurosci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0091","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/hum.2015.130","article-title":"Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases","volume":"27","author":"Ye","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0092","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/mt.2013.232","article-title":"Successful gene therapy in the RPGRIP1-deficient dog: a large model of cone-rod dystrophy","volume":"22","author":"Lheriteau","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0093","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ophtha.2011.10.011","article-title":"Clinical course, genetic etiology, and visual outcome in cone and cone-rod dystrophy","volume":"119","author":"Thiadens","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajps.2022.02.001_bib0094","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.05.001","article-title":"Causes and consequences of inherited cone disorders","volume":"42","author":"Roosing","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0095","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3390\/cells9071608","article-title":"Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing","volume":"9","author":"Naeem","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ajps.2022.02.001_bib0096","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004838117","article-title":"Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito","volume":"118","author":"Garrood","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajps.2022.02.001_bib0097","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2020.574959","article-title":"Which factors affect the occurrence of off-target effects caused by the use of CRISPR\/Cas: a systematic review in plants","volume":"11","author":"Modrzejewski","year":"2020","journal-title":"Front Plant Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0098","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.657981","article-title":"The challenge of CRISPR-Cas toward bioethics","volume":"12","author":"Gonzalez-Avila","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0099","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1073\/pnas.1922925117","article-title":"Understanding the genetic architecture of human retinal degenerations","volume":"117","author":"Hejtmancik","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajps.2022.02.001_bib0100","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0101","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fgene.2018.00691","article-title":"Methodologies for improving HDR efficiency","volume":"9","author":"Liu","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.ajps.2022.02.001_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100845","article-title":"No flow through the vitreous humor: how strong is the evidence?","volume":"78","author":"Smith","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0103","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/acs.bioconjchem.7b00057","article-title":"In vivo delivery of CRISPR\/Cas9 for therapeutic gene editing: progress and challenges","volume":"28","author":"Mout","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ajps.2022.02.001_bib0104","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0105","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat Methods"},{"key":"10.1016\/j.ajps.2022.02.001_bib0106","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajps.2022.02.001_bib0107","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0108","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Na Nanotechnol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0109","article-title":"Efficient homology-directed gene editing by CRISPR\/Cas9 in human stem and primary cells using tube electroporation","volume":"8","author":"Xu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajps.2022.02.001_bib0110","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1021\/acsnano.6b07600","article-title":"Direct cytosolic delivery of CRISPR\/Cas9-ribonucleoprotein for efficient gene editing","volume":"11","author":"Mout","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2022.02.001_bib0111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0112","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0113","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-biochem-060713-035418","article-title":"Genome engineering with targetable nucleases","volume":"83","author":"Carroll","year":"2014","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.ajps.2022.02.001_bib0114","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ajps.2022.02.001_bib0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ajps.2022.02.001_bib0116","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1101\/gr.171264.113","article-title":"Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA","volume":"24","author":"Ramakrishna","year":"2014","journal-title":"Genome Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0117","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0118","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jop.2012.0200","article-title":"Novel strategies for anterior segment ocular drug delivery","volume":"29","author":"Cholkar","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0119","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.preteyeres.2009.12.002","article-title":"The multifunctional choroid","volume":"29","author":"Nickla","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0120","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0121","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/08820538.2014.962167","article-title":"Complications of intravitreal injections in patients with diabetes","volume":"29","author":"Shikari","year":"2014","journal-title":"Semin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajps.2022.02.001_bib0122","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3390\/ijms19092830","article-title":"Ocular drug delivery: role of degradable polymeric nanocarriers for ophthalmic application","volume":"19","author":"Tsai","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ajps.2022.02.001_bib0123","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations","volume":"12","author":"Varela-Fernandez","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ajps.2022.02.001_bib0124","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: an overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J Pharmacol"},{"issue":"9","key":"10.1016\/j.ajps.2022.02.001_bib0125","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/pharmaceutics11090460","article-title":"Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents","volume":"11","author":"Souto","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ajps.2022.02.001_bib0126","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"Hgh-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0127","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2017.11.012","article-title":"Engineering protein-secreting plasma cells by homology-directed repair in primary human B cells","volume":"26","author":"Hung","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-59745-194-9_6","article-title":"Overview of drug delivery and alternative methods to electroporation","volume":"423","author":"Hui","year":"2008","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8831-0_1","article-title":"Microinjection and micromanipulation: a historical perspective","volume":"1874","author":"Xu","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0130","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.drudis.2019.02.001","article-title":"Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties","volume":"24","author":"Subrizi","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ajps.2022.02.001_bib0131","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.bpj.2015.10.002","article-title":"Diffusion regulation in the vitreous humor","volume":"109","author":"K\u00e4sdorf","year":"2015","journal-title":"Biophys J"},{"key":"10.1016\/j.ajps.2022.02.001_bib0132","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.molpharmaceut.0c00411","article-title":"Diffusion and protein corona formation of lipid-based nanoparticles in the vitreous humor: profiling and pharmacokinetic considerations","volume":"18","author":"Tavakoli","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ajps.2022.02.001_bib0133","article-title":"Polysaccharide-based nanomaterials for ocular drug delivery: a perspective","volume":"8","author":"Yu","year":"2020","journal-title":"Fron Bioeng Biotechnol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0134","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","article-title":"Delivery aspects of CRISPR\/Cas for in vivo genome editing","volume":"52","author":"Wilbie","year":"2019","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0135","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1089\/hum.2015.069","article-title":"Challenges in CRISPR\/CAS9 delivery: potential roles of nonviral vectors","volume":"26","author":"Li","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0136","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0137","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0138","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nbt.3149","article-title":"A split-Cas9 architecture for inducible genome editing and transcription modulation","volume":"33","author":"Zetsche","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0139","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0140","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1167\/iovs.05-0965","article-title":"RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-\/- mice","volume":"47","author":"Chen","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0141","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ymthe.2005.09.001","article-title":"Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis","volume":"13","author":"Pang","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0142","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Human Gene Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0143","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0144","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature14592","article-title":"Engineered CRISPR-Cas9 nucleases with altered PAM specificities","volume":"523","author":"Kleinstiver","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ajps.2022.02.001_bib0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ajps.2022.02.001_bib0146","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nmeth.2681","article-title":"Orthogonal Cas9 proteins for RNA-guided gene regulation and editing","volume":"10","author":"Esvelt","year":"2013","journal-title":"Nat Methods"},{"key":"10.1016\/j.ajps.2022.02.001_bib0147","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2015.087","article-title":"Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses","volume":"26","author":"Wang","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0148","first-page":"137","article-title":"Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo","volume":"3","author":"Yang","year":"1996","journal-title":"Gene Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0149","first-page":"2224","article-title":"Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery","volume":"38","author":"Hoffman","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108071","article-title":"Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications","volume":"9","author":"Ueyama","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ajps.2022.02.001_bib0151","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.gt.3301680","article-title":"Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1","volume":"9","author":"Bainbridge","year":"2002","journal-title":"Gene Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0152","first-page":"1358","article-title":"A reproducible and quantifiable model of choroidal neovascularization induced by VEGF A165 after subretinal adenoviral gene transfer in the rabbit","volume":"14","author":"Julien","year":"2008","journal-title":"Mol Vis"},{"key":"10.1016\/j.ajps.2022.02.001_bib0153","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3892\/ijmm.2012.1197","article-title":"Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model","volume":"31","author":"Wang","year":"2013","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0154","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1128\/jvi.66.10.5906-5913.1992","article-title":"Wild-type equine infectious anemia virus replicates in vivo predominantly in tissue macrophages, not in peripheral blood monocytes","volume":"66","author":"Sellon","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0155","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet (Lond)"},{"key":"10.1016\/j.ajps.2022.02.001_bib0156","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.gt.3302897","article-title":"Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B","volume":"14","author":"Hashimoto","year":"2007","journal-title":"Gene Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0157","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jgm.845","article-title":"Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors","volume":"8","author":"Balaggan","year":"2006","journal-title":"J Gene Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0158","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-4939-7795-6_8","article-title":"Targeted genome editing using DNA-free RNA-guided Cas9 ribonucleoprotein for CHO cell engineering","volume":"1772","author":"Shin","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-004-9003-5","article-title":"Polyethylene glycol-conjugated copolymers for plasmid DNA delivery","volume":"22","author":"Lee","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0163","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","article-title":"Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure","volume":"84","author":"Felgner","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajps.2022.02.001_bib0164","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2022.02.001_bib0165","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1073\/pnas.1520244113","article-title":"Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajps.2022.02.001_bib0166","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/acs.accounts.8b00493","article-title":"Integrating combinatorial lipid nanoparticle and chemically modified protein for intracellular delivery and genome editing","volume":"52","author":"Chang","year":"2019","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.ajps.2022.02.001_bib0167","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajps.2022.02.001_bib0168","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.ajps.2022.02.001_bib0169","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/jgm.696","article-title":"Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis","volume":"7","author":"Akinc","year":"2005","journal-title":"J Gene Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0170","doi-asserted-by":"crossref","DOI":"10.1002\/marc.201800068","article-title":"Cationic Polymer-mediated CRISPR\/Cas9 plasmid delivery for genome editing","volume":"40","author":"Zhang","year":"2019","journal-title":"Macromol Rapid Commun"},{"key":"10.1016\/j.ajps.2022.02.001_bib0171","doi-asserted-by":"crossref","first-page":"12029","DOI":"10.1002\/anie.201506030","article-title":"Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing","volume":"54","author":"Sun","year":"2015","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.ajps.2022.02.001_bib0172","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1166\/jbn.2015.2069","article-title":"Polymeric nanocarriers for non-viral gene delivery","volume":"11","author":"Li","year":"2015","journal-title":"J Bio med Nanotechnol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0173","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1021\/bc9701510","article-title":"Characterization of interpolyelectrolyte complexes between double-stranded DNA and polylysine comb-type copolymers having hydrophilic side chains","volume":"9","author":"Maruyama","year":"1998","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ajps.2022.02.001_bib0174","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"6","key":"10.1016\/j.ajps.2022.02.001_bib0175","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/pharmaceutics12060561","article-title":"pH-responsive, cell-penetrating, core\/shell magnetite\/silver nanoparticles for the delivery of plasmids: preparation, characterization, and preliminary in vitro evaluation","volume":"12","author":"Ramirez-Acosta","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ajps.2022.02.001_bib0176","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","article-title":"A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing","volume":"14","author":"Chen","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.ajps.2022.02.001_bib0177","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0975-7406.130965","article-title":"Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues","volume":"6","author":"Madaan","year":"2014","journal-title":"J Pharm Bioallied Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0178","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/psc.1347","article-title":"Low-generation asymmetric dendrimers exhibit minimal toxicity and effectively complex DNA","volume":"17","author":"Shah","year":"2011","journal-title":"J Pept Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0179","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1002\/anie.201203920","article-title":"An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in vitro and in vivo","volume":"51","author":"Yu","year":"2012","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.ajps.2022.02.001_bib0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jconrel.2004.07.027","article-title":"Enhanced transfection efficiency of PAMAM dendrimer by surface modification with l-arginine","volume":"99","author":"Choi","year":"2004","journal-title":"J Control Rel"},{"key":"10.1016\/j.ajps.2022.02.001_bib0181","doi-asserted-by":"crossref","first-page":"eaaw8922","DOI":"10.1126\/sciadv.aaw8922","article-title":"A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing","volume":"5","author":"Liu","year":"2019","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.ajps.2022.02.001_bib0182","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/ijms21030777","article-title":"RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences","volume":"21","author":"Fry","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajps.2022.02.001_bib0183","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.ophtha.2017.04.008","article-title":"Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease","volume":"124","author":"Stone","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajps.2022.02.001_bib0184","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/wsbm.10","article-title":"Adenosine-to-inosine RNA editing","volume":"1","author":"Zinshteyn","year":"2009","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"10.1016\/j.ajps.2022.02.001_bib0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fgene.2018.00134","article-title":"Commentary: RNA editing with CRISPR-Cas13","volume":"9","author":"Matsoukas","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.ajps.2022.02.001_bib0186","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fgene.2015.00362","article-title":"Advanced in vivo use of CRISPR\/Cas9 and anti-sense DNA inhibition for gene manipulation in the brain","volume":"6","author":"Walters","year":"2016","journal-title":"Front Genet"}],"container-title":["Asian Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087622000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087622000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:40:06Z","timestamp":1778827206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1818087622000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":184,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1818087622000149"],"URL":"https:\/\/doi.org\/10.1016\/j.ajps.2022.02.001","relation":{},"ISSN":["1818-0876"],"issn-type":[{"value":"1818-0876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery strategies for CRISPR\/Cas genome editing tool for retinal dystrophies: challenges and opportunities","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajps.2022.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Shenyang Pharmaceutical University. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}